Nanoparticles as Contrast Agents for The Diagnosis of Alzheimer’s Disease: A Systematic Review
Marina Ulanova, Anne Poljak, Wei Wen, André Bongers, Lucy Gloag, J. Justin Gooding, Richard D. Tilley, Perminder S. Sachdev, Nady Braidy
Abstract
Nanoparticle (NP)-based magnetic contrast agents have opened the potential for MRI to be used for early diagnosis of Alzheimer's disease (AD). This article aims to review the current progress of research in this field. A comprehensive literature search was performed based on PubMed, Medline, EMBASE, PsychINFO and Scopus databases using the following terms: 'Alzheimer's disease' AND 'nanoparticles' AND 'Magnetic Resonance Imaging.' 33 studies were included that described the development and utility of various NPs for AD imaging, including their coating, functionalization, MRI relaxivity, toxicity and bioavailability. NPs show immense promise for neuroimaging, due to superior relaxivity and biocompatibility compared with currently available imaging agents. Consistent reporting is imperative for further progress in this field.